Cytokinetics, Incorporated awaits a pivotal FDA decision on aficamten for hypertrophic cardiomyopathy. Learn more about CYTK ...

Right now, the HALT Study is underway to provide the substantial evidence of effectiveness necessary for the full FDA approval of Felycin-CA1 (referred to as TRIV202 in HALT) for the management of ...

Extra scrutiny is warranted to identify the underlying causes of chest pain in patients with nonobstructive coronary disease ...

Patients with undiagnosed sleep disordered breathing and hypertrophic cardiomyopathy may have subclinical myocardial injury.

Cytokinetics may be counting down the days until the FDA decides whether to approve its cardiovascular drug aficamten. | ...

Bristol Myers BMY announced that it will discontinue the late-stage Librexia study evaluating the efficacy and safety of ...

Chest pain may still be angina even when the main heart arteries look clear. Using cardiac stress MRI (a heart scan that measures blood flow with magnetic resonance imaging), testing uncovered small ...

Three Late Breaking Science Presentations from MAPLE-HCM Provide Additional Data Including Responder Analyses, Patient Reported Outcomes, and Cardiac Biomarkers ...

Imbria Pharmaceuticals has randomised the first participant in FORTITUDE HCM, a Phase IIb trial of ninerafaxstat in symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM), a condition for ...

Bristol Myers Squibb currently has the only drug approved specifically for treating obstructive hypertrophic cardiomyopathy, a debilitating disorder that can progress to heart failure. But safety ...